Entrada Therapeutics, Inc. financial data

Symbol
TRDA on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Design Center Place, Suite 17 500, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Former names
CycloPorters, Inc. (to 11/10/2016)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 284 % -29.1%
Debt-to-equity 72.3 % +3.88%
Return On Equity 35.2 %
Return On Assets 20.4 %
Operating Margin 39 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.2M shares +11.8%
Common Stock, Shares, Outstanding 37.2M shares +11.9%
Entity Public Float 431M USD +57.1%
Common Stock, Value, Issued 4K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 34.2M shares +3.07%
Weighted Average Number of Shares Outstanding, Diluted 35.5M shares +7.07%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 239M USD +421%
Research and Development Expense 111M USD +32.2%
General and Administrative Expense 34.8M USD +5.58%
Operating Income (Loss) 93.5M USD
Income Tax Expense (Benefit) 5.93M USD -65.9%
Net Income (Loss) Attributable to Parent 104M USD
Earnings Per Share, Basic 3.1 USD/shares
Earnings Per Share, Diluted 3.02 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 185M USD +132%
Marketable Securities, Current 162M USD
Cash, Cash Equivalents, and Short-term Investments 470M USD +24.7%
Assets, Current 490M USD +25.5%
Property, Plant and Equipment, Net 11.3M USD +2.96%
Operating Lease, Right-of-Use Asset 76.4M USD -13.5%
Other Assets, Noncurrent 747K USD +38.8%
Assets 582M USD +17.8%
Accounts Payable, Current 1.64M USD -32.5%
Employee-related Liabilities, Current 3.59M USD +30.8%
Accrued Liabilities, Current 11M USD +54.8%
Liabilities, Current 85.8M USD -31.9%
Operating Lease, Liability, Noncurrent 55.9M USD -14.9%
Liabilities 152M USD -47%
Accumulated Other Comprehensive Income (Loss), Net of Tax -329K USD +67.3%
Retained Earnings (Accumulated Deficit) -116M USD +47.3%
Stockholders' Equity Attributable to Parent 430M USD +108%
Liabilities and Equity 582M USD +17.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.5M USD -113%
Net Cash Provided by (Used in) Financing Activities 206K USD -98.9%
Net Cash Provided by (Used in) Investing Activities 26.1M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 37.2M shares +11.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 834K USD -99.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 189M USD +126%
Deferred Tax Assets, Valuation Allowance 77.9M USD +35.7%
Deferred Tax Assets, Gross 102M USD +57.9%
Operating Lease, Liability 68.2M USD +163%
Depreciation 3.43M USD +52.9%
Payments to Acquire Property, Plant, and Equipment 838K USD -49.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 105M USD
Lessee, Operating Lease, Liability, to be Paid 94.6M USD +246%
Property, Plant and Equipment, Gross 18.9M USD +23.3%
Operating Lease, Liability, Current 8.57M USD +15.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 13.2M USD +38.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 13.1M USD +41.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +105%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 26.4M USD +1748%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.83M USD +2.04%
Deferred Tax Assets, Operating Loss Carryforwards 3.62M USD -88.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 9.08M USD
Operating Lease, Payments 2.28M USD +24.1%
Additional Paid in Capital 547M USD +27.5%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 15.6M USD +36%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%